Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker STOK
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Morgan Stanley Capital Services LLC | 2.65M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Morgan Stanley | 3.18M | 4.9% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Abigail P. Johnson | 4.82M | 7.5% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | FMR LLC | 4.82M | 7.5% | SCHEDULE 13G/A ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Mark N. Lampert | 3.61M | 5.6% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF Inc/Il | 3.61M | 5.6% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF Partners L P/Il | 3.61M | 5.6% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF GP Holdings LLC | 3.27M | 5.1% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF Partners OS Ltd. | 261,006 | 0.4% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Biotechnology Value Trading Fund OS LP | 261,006 | 0.4% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF II GP LLC | 1.40M | 2.2% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Biotechnology Value Fund II LP | 1.40M | 2.2% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | BVF I GP LLC | 1.87M | 2.9% | SCHEDULE 13G ↗ |
| Sep 30, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Biotechnology Value Fund L P | 1.87M | 2.9% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Weston Nichols | 4.04M | 6.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Lynx1 Capital Management LP | 4.04M | 6.5% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | TD Securities Inc. | 10,000 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | The Toronto-Dominion Bank | 3.17M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Abigail P. Johnson | 5.31M | 8.5% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | FMR LLC | 5.31M | 8.5% | SCHEDULE 13G/A ↗ |
| May 18, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Weston Nichols | 4.76M | 8.1% | SCHEDULE 13G/A ↗ |
| May 18, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Lynx1 Capital Management LP | 4.76M | 8.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Roderick Wong | 5.94M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | RTW Investments, LP | 5.94M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Redmile Biopharma Investments III, L.P. | 3.51M | 5.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Jeremy C. Green | 4.16M | 6.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Redmile Group, LLC | 4.16M | 6.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | TD Securities Inc. | 2,300 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | The Toronto-Dominion Bank | 3.17M | 5.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Weston Nichols | 4.12M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Lynx1 Capital Management LP | 4.12M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Wellington Management Company LLP | 3.10M | 5.1% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Wellington Investment Advisors Holdings LLP | 3.10M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Wellington Group Holdings LLP | 3.10M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | Wellington Management Group LLP | 3.10M | 5.2% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Felix J. Baker | 3.34M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Julian C. Baker | 3.34M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Baker Bros. Advisors (GP) LLC | 3.34M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Baker Bros. Advisors LP | 3.34M | 5.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Abigail P. Johnson | 5.60M | 9.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | FMR LLC | 5.60M | 9.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Cowen Financial Products LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G | STOK Stoke Therapeutics, Inc. | The Toronto-Dominion Bank | 3.17M | 5.8% | SCHEDULE 13G ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | Abigail P. Johnson | 6.87M | 12.5% | SCHEDULE 13G/A ↗ |
| Nov 5, 2025 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | FMR LLC | 6.87M | 12.5% | SCHEDULE 13G/A ↗ |
| Oct 17, 2025 | SCHEDULE 13G/A (amended) | STOK Stoke Therapeutics, Inc. | BlackRock, Inc. | 3.73M | 6.8% | SCHEDULE 13G/A ↗ |
| Aug 26, 2025 | SCHEDULE 13D/A (amended) | STOK Stoke Therapeutics, Inc. | Skorpios Trust | 2.26M | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 26, 2025 | SCHEDULE 13D/A (amended) | STOK Stoke Therapeutics, Inc. | Montrago Trustees Ltd | 2.26M | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 26, 2025 | SCHEDULE 13D/A (amended) | STOK Stoke Therapeutics, Inc. | Ezbon International Ltd | 288,560 | 0.5% | SCHEDULE 13D/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances